Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott's Absorb GT1 Is First FDA-Approved Absorbable Coronary Stent

Executive Summary

Following the near-unanimous advice of its advisory panel, the US FDA approved Abbott Laboratories’ Absorb GT1 everolimus-eluting biodegradable poly(L-lactide) scaffold, making it the first bioresorbable coronary stent commercially available in the US.


Related Content

ACC 2017: Disappointing Absorb Results Blamed On Implant Approach
TCT 2016: Three-Year ABSORB II Data Fail To Show The Hoped-For Long-Term Benefit Of Bioresorbable Stent
Expert Webinar Explores Pressing Questions About Biosorbable Stent Technology
Robert Byrne: Absorb, Synergy, And The Future Of Coronary Stents


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts